ASXL1/TET2 Genotype-Based Risk Stratification Outperforms ASXL1 Mutational Impact and Is Independent of Mutant Variant Allele Fractions in Chronic Myelomonocytic Leukemia

Authors

Clifford M Csizmar
Mark Gurney
Rashmi Kanagal-Shamanna
Kelly Chien
Danielle Hammond
Terra L Lasho
Christy M Finke
Christopher Dean
Anuya Natu
Abhishek A Mangaonkar
Aref Al-Kali
Naseema Gangat
Ayalew Tefferi
Hassan Alkhateeb
Guillermo Garcia-Manero
Rami S Komrokji
Najla A Ali
Eric Padron
Guillermo Montalban-Bravo
Mrinal M Patnaik

Language

English

Publication Date

10-1-2024

Journal

Haematologica

DOI

10.3324/haematol.2024.285410

PMID

38899337

PMCID

PMC11443373

PubMedCentral® Posted Date

6-20-2024

PubMedCentral® Full Text Version

Post-print

Keywords

Humans, Leukemia, Myelomonocytic, Chronic, Mutation, Repressor Proteins, Dioxygenases, Alleles, DNA-Binding Proteins, Proto-Oncogene Proteins, Genotype, Risk Assessment, Male, Female, Prognosis

Published Open-Access

yes

Recommended Citation

Csizmar, Clifford M; Gurney, Mark; Kanagal-Shamanna, Rashmi; et al., "ASXL1/TET2 Genotype-Based Risk Stratification Outperforms ASXL1 Mutational Impact and Is Independent of Mutant Variant Allele Fractions in Chronic Myelomonocytic Leukemia" (2024). Faculty, Staff and Student Publications. 5702.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/5702